ÂÜÀòÂÒÂ×

Hazel Jones serves as Chief Executive Officer and Chief Operating Officer at ENHANC3D GENOMICS since October 2023. Prior to this role, Hazel held significant positions at AstraZeneca from September 2016 to January 2023, including Executive Product Director for Clinical Data and Head of Business Planning and Operations within Oncology R&D, where responsibilities included steering strategic agendas and fostering cross-functional partnerships. Previously, Hazel was Oncology Chief of Staff at Cancer Research UK, managing early phase combination trials and expanding collaborative partnerships significantly, and held the position of Head of Functional Pharmacology at Cancer Research Technology, overseeing a team of scientists and managing a diverse small molecule portfolio. With foundational experience as a Senior Scientist at MedImmune and earlier roles at Cambridge Antibody Technology and Xenova, Hazel has built extensive expertise in oncology pharmacology and clinical research. Educational background includes a PhD in Biochemistry from the University of Leeds and a BSc in Pharmacology from The University of Sheffield.